Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
08/2003
08/26/2003US6610854 Reacting (Z)-5-Fluoro-2-methyl-(4-pyridylidene)-3-(N-benzyl) indenylacetamide with hydrochloric acid to produce (Z)-5-fluoro-2-methyl-(4-pyridylidene)-3-(N-benzyl)indenylacetamide hydrochloride
08/26/2003US6610847 Tyrosine kinase inhibitors; immunosuppressants
08/26/2003US6610839 Promoter for telomerase reverse transcriptase
08/26/2003US6610829 Human extracellular matrix-1
08/26/2003US6610821 Cyclic peptide of given amino acid sequence; can use to improve drug delivery process, inhibit angiogenesis, increase vasopermeability; treatment of autoimmune and inflammatory diseases
08/26/2003US6610820 Cell-permeable peptide inhibitors of the JNK signal transduction pathway
08/26/2003US6610745 Use of 2-hydroxy-4-trifluoromethyl-benzoic acid derivatives as inhibitors of the activation of the nuclear transcription factor NF-KS
08/26/2003US6610744 Methods of treatment with compounds having RARα receptor specific or selective activity
08/26/2003US6610736 16-Halogen-epothilone derivatives, method for producing them and their pharmaceutical use
08/26/2003US6610735 Coadministration of a an oral bioavailability-enhancing agent (e.g., a cyclosporin F or ketoconazole) with a drug that exhibits poor or inconsistent oral bioavailability (e.g., paclitaxel, docetaxel or etoposide)
08/26/2003US6610733 Optically active chroman and thiochroman derivatives
08/26/2003US6610727 Antitumor agents
08/26/2003US6610724 3-Aminopyrazole inhibitors of cyclin dependent kinases
08/26/2003US6610699 Use of L-carnitine and its alkanoyl derivatives in the preparation of medicaments with anticancer activity
08/26/2003US6610688 For therapy of blood vessel proliferative disorders; fibrotic disorders; mesangial cell proliferative disorders; metabolic disorders; allergies; asthma; thrombosis; nervous system diseases; and cancer
08/26/2003US6610684 Fused azepinone cyclin dependent kinase inhibitors
08/26/2003US6610660 O2-arylated or O2-glycosylated 1-substituted diazen-1-ium-1,2-diolates and O2-substituted 1-[(2-carboxylato) pyrrolidin-1-yl] diazen-1-ium-1,2-diolates
08/26/2003US6610650 Modulation of cellular transcription factor activity
08/26/2003US6610541 Recombinant, active caspases and uses thereof
08/26/2003US6610512 Zinc finger binding domains for GNN
08/26/2003US6610477 Human DNA mismatch repair proteins
08/26/2003US6610473 Peptides for inhibiting HPV E6-proteins
08/26/2003US6610309 Vaccines; mixture of antigen and water solubility organometallic compound
08/26/2003US6610303 Papilloma viruses, products for the detection thereof as well as for treating diseases caused by them
08/26/2003US6610294 Methods of inhibiting an autoimmune response in a human suffering from an autoimmune disease by administering an antibody that binds to a protein to which monoclonal antibody 5C8 binds
08/25/2003CA2419773A1 Matrix metalloproteinase and tumor necrosis factor inhibitors
08/25/2003CA2405347A1 Medicament comprising nk4 gene or recombinant nk4 protein
08/21/2003WO2003069350A2 Small molecule modulators of apoptosis
08/21/2003WO2003068970A1 Sodium-independent transporter carrying acidic amino acid and its gene
08/21/2003WO2003068959A1 Novel screening method
08/21/2003WO2003068957A1 METHOD OF SCREENING INK4 FAMILY GENE EXPRESSION CONTROLLER AND p19 GENE PROMOTER
08/21/2003WO2003068954A2 Microorganism for genetic therapeutic treatment of proliferative diseases
08/21/2003WO2003068952A1 Stat3 activated stem cell
08/21/2003WO2003068946A1 Phenalenone derivatives, method for the production thereof and use of the same
08/21/2003WO2003068941A2 Modulation of immune response by non-peptide binding stress response polypeptides
08/21/2003WO2003068939A2 Cks1 INHIBITORS
08/21/2003WO2003068936A2 Inhibition of lung metastases by aerosol delivery of p53 gene and anti-cancer compounds
08/21/2003WO2003068811A2 Cytotoxic t-cell epitopes from chlamydia
08/21/2003WO2003068809A2 An herpes simplex virus complex
08/21/2003WO2003068794A1 Nucleoside analogues whose sugar moieties are bound in s-form and oligonucleotide derivatives comprising nucleotide analogues thereof
08/21/2003WO2003068769A1 Non-peptide compounds affecting the action of gonadotropin-releasing hormone (gnrh)
08/21/2003WO2003068768A1 Imidazole 4-carboxamide compounds with adenosine deaminase inhibiting activity
08/21/2003WO2003068754A1 Therapeutic substituted indazole derivatives
08/21/2003WO2003068750A1 Jnk inhibitor
08/21/2003WO2003068747A1 Nicotinamide derivates useful as p38 inhibitors
08/21/2003WO2003068746A1 Aryl ureas as kinase inhibitors
08/21/2003WO2003068743A1 Chemical compounds
08/21/2003WO2003068742A1 Synthesis of indole thiazole compounds as ligands for the ah receptor
08/21/2003WO2003068287A1 Compositions comprising undifferentiated fetal cells for the treatment of skin disorders
08/21/2003WO2003068270A1 Method of radio-labelling biomolecules
08/21/2003WO2003068265A1 Methods and compositions for treating hyperproliferative conditions
08/21/2003WO2003068258A1 7s immunoglobulin for treatment of choroidal neovascularisation_
08/21/2003WO2003068257A1 Cancer therapy
08/21/2003WO2003068249A1 Shark cartilage extracts and use thereof for immunomodulation
08/21/2003WO2003068235A1 Nicotinamide derivatives useful as pde4 inhibitors
08/21/2003WO2003068234A1 Nicotinamide derivatives and a tiotropium salt in combination for the treatment of e.g. inflammatory, allergic and respiratory diseases
08/21/2003WO2003068232A1 Nicotinamide derivatives useful as pde4 inhibitors
08/21/2003WO2003068230A1 Substituted pyridinones as modulators of p38 map kinase
08/21/2003WO2003068229A1 Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors
08/21/2003WO2003068228A1 Aryl ureas with angiogenesis inhibiting activity
08/21/2003WO2003068224A2 Use of inhibitors of the sodium-dependent chloride-bicarbonate-exchanger for treating thrombotic and inflammatory diseases
08/21/2003WO2003068223A1 Aryl ureas with raf kinase and angiogenesis inhibiting activity
08/21/2003WO2003068219A1 Use of anethole dithiolethione in lung cancer chemoprevention
08/21/2003WO2003068218A1 Use of genistein in the manufacture of a medicament for the treatment of osteoporosis and obesity, and compositions containing genistein in combination with vitamin d and k
08/21/2003WO2003068217A1 Biphenil derivatives and their use as antiandrogenic agents
08/21/2003WO2003068212A1 Use of sodium/hydrogen exchange inhibitors from the treatment of thrombotic and inflammatory diseases
08/21/2003WO2003068210A1 N-acyl-phosphatidyl-ethanolamines and/or mixtures of n-acyl-ethanolamines with phosphatidic acids or lysophosphatidic acids
08/21/2003WO2003068202A1 Compositions comprising lycopene for the treatment and prevention of angiogenesis associated pathologies
08/21/2003WO2003068197A1 Method for systemic drug delivery through the nail
08/21/2003WO2003068169A2 Stabilized synthetic immunogen delivery system
08/21/2003WO2003068164A2 Dosing regimen for gemcitabine hcv therapy
08/21/2003WO2003068162A2 Modified fluorinated nucleoside analogues
08/21/2003WO2003068146A2 Identification of actinobacillus actinomycetemcomitans antigens for use in the diagnosis, treatment, and monitoring of periodontal diseases
08/21/2003WO2003068144A2 Cytotoxic agents
08/21/2003WO2003068140A2 Novel pyridazine derivatives, use of the same as medicaments, pharmaceutical compositions and method for producing the same
08/21/2003WO2003060142A9 Compositions and methods for controlled release
08/21/2003WO2003055913A3 Secreted protein
08/21/2003WO2003048352A3 Histone h3 methyltransferase polypeptide
08/21/2003WO2003047579B1 Aryl urea compounds in combination with other cytostatic or cytotoxic agents for treating human cancers
08/21/2003WO2003045227A3 Single nucleotide polymorphisms and combinations thereof predictive for paclitaxel responsiveness
08/21/2003WO2003039479A3 Polymeric thiol-linked prodrugs
08/21/2003WO2003033674A3 Human antibodies that have mn binding and cell adhesion-neutralizing activity
08/21/2003WO2003029451A3 Histone deacetylase 9
08/21/2003WO2003027075A3 Substituted pyrazolyl benzenesulfamide compounds for the treatment of inflammation
08/21/2003WO2003025176B1 Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines
08/21/2003WO2003024935A3 Substituted pyrazolyl compounds for the treatment of inflammation
08/21/2003WO2003024474A3 Anti-inflammatory agent
08/21/2003WO2003024404A3 Chemokines as adjuvants of immune response
08/21/2003WO2003020751A3 Homing peptides
08/21/2003WO2003020217A3 Novel pyrazole analogs acting on cannabinoid receptors
08/21/2003WO2003013488A3 Methods and compositions for inhibiting rad51
08/21/2003WO2003007930A3 Use of sulfonyl aryl or heteroaryl hydroxamic acids and derivatives thereof as aggrecanase inhibitors
08/21/2003WO2003006070A3 Improved chelator conjugates
08/21/2003WO2003004006A8 Use of potent, selective and non toxic c-kit inhibitors for treating tumor angiogenesis
08/21/2003WO2002092620A3 Peptides and related molecules that bind to tall-1
08/21/2003WO2002088664A3 Control of compactability through crystallization
08/21/2003WO2002085384A3 Lubricious coatings for substrates
08/21/2003WO2002085311A3 Hcg formulation
08/21/2003WO2002077236A3 Compositions and methods relating to lung specific genes and proteins
08/21/2003WO2002067861A3 Oncolytic adenoviral vectors
1 ... 1524 1525 1526 1527 1528 1529 1530 1531 1532 1533 1534 1535 1536 1537 1538 1539 1540 1541 1542 1543 1544 ... 2211